GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (NAS:CLLS) » Definitions » Cyclically Adjusted Price-to-FCF

CLLS (Cellectis) Cyclically Adjusted Price-to-FCF : (As of May. 25, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Cellectis Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cellectis Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Cellectis's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectis Cyclically Adjusted Price-to-FCF Chart

Cellectis Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cellectis Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cellectis's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Cellectis's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cellectis's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cellectis's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Cellectis's Cyclically Adjusted Price-to-FCF falls into.


;
;

Cellectis Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Cellectis's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Cellectis's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.175/120.3800*120.3800
=-0.175

Current CPI (Mar. 2025) = 120.3800.

Cellectis Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -0.532 100.440 -0.638
201509 -0.154 99.950 -0.185
201512 0.788 100.040 0.948
201603 -0.844 100.020 -1.016
201606 -0.363 100.630 -0.434
201609 -0.123 100.340 -0.148
201612 0.015 100.650 0.018
201703 -0.477 101.170 -0.568
201706 -0.334 101.320 -0.397
201709 -0.453 101.330 -0.538
201712 -0.279 101.850 -0.330
201803 -0.572 102.750 -0.670
201806 -0.310 103.370 -0.361
201809 -0.383 103.560 -0.445
201812 -0.544 103.470 -0.633
201903 -0.570 103.890 -0.660
201906 -0.571 104.580 -0.657
201909 -0.662 104.500 -0.763
201912 -0.130 104.980 -0.149
202003 -0.153 104.590 -0.176
202006 -0.852 104.790 -0.979
202009 -0.752 104.550 -0.866
202012 -1.175 104.960 -1.348
202103 -1.146 105.750 -1.305
202106 -0.387 106.340 -0.438
202109 -0.789 106.810 -0.889
202112 -0.451 107.850 -0.503
202203 -0.819 110.490 -0.892
202206 -0.543 112.550 -0.581
202209 -0.586 112.740 -0.626
202212 -0.032 114.160 -0.034
202303 -0.555 116.790 -0.572
202306 -0.377 117.650 -0.386
202309 -0.284 118.260 -0.289
202312 0.603 118.390 0.613
202403 -0.229 119.470 -0.231
202406 0.569 120.200 0.570
202409 -0.066 119.560 -0.066
202412 -0.018 119.950 -0.018
202503 -0.175 120.380 -0.175

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cellectis  (NAS:CLLS) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Cellectis Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Cellectis's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Cellectis Business Description

Industry
Address
8, rue de la Croix Jarry, Paris, FRA, 75013
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.